Indeed, we find that TP53 LOH is a frequent event in human cancers with missense mutp53, including sarcomas (61%), breast cancer with or without HER2 amplification (up to 82%) and ovarian cancer (75%) (Figure 1, Tables 1 and 2). This evidence concerns the gene TP53 and ovarian carcinoma.